Rhumbline Advisers Cassava Sciences Inc Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
A detailed history of Rhumbline Advisers transactions in Cassava Sciences Inc stock. As of the latest transaction made, Rhumbline Advisers holds 59,259 shares of SAVA stock, worth $1.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
59,259
Previous 56,937
4.08%
Holding current value
$1.5 Million
Previous $1.16 Million
36.71%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding SAVA
# of Institutions
189Shares Held
13.5MCall Options Held
1.38MPut Options Held
2.26M-
Black Rock Inc. New York, NY3.22MShares$81.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.68MShares$68 Million0.0% of portfolio
-
State Street Corp Boston, MA1.18MShares$29.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA967KShares$24.5 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA691KShares$17.5 Million0.0% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $1.02B
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...